# OnCo record nct04025879 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04025879/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04025879", "NCT04025879" ;
  schema:name "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer"@en ;
  schema:alternateName "CheckMate 77T"@en ;
  schema:description "A phase 3 trial of Nivolumab, Carboplatin, Cisplatin, Pemetrexed and Docetaxel in non-small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04025879/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04025879>, <https://doi.org/10.1056/NEJMoa2311926>, <https://www.nice.org.uk/guidance/ta1127> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2019-11-05" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/checkmate-816/>, <https://onco.cc/trials/keynote-671/>, <https://onco.cc/trials/nct03800134/>, <https://onco.cc/trials/neotorch/>, <https://onco.cc/trials/nct04379635/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04025879-n-engl-j-med-2024/> .